Key Highlights

  • AXT (NASDAQ:AXTI) shares fell 12.90% to USD 30.35 on November 20, 2026.
  • Record third quarter Revenue was USD 73.4 million, up 162%.
  • The indium phosphide Backlog is above USD 500 million.
  • Lumentum made a USD 43.5 million prepayment.

An Optical Rout Hits a China-Exposed Supplier

AXT (NASDAQ:AXTI), a maker of indium phosphide and other compound semiconductor wafers used in AI optical links, fell 12.90% to USD 30.35 on November 20, 2026, on Volume of 7.84 million shares. No company-specific announcement appeared on the day. Pressure on AI-linked optical names was broad, with Lumentum down about 9.5% and Ciena about 8%, and the Philadelphia Semiconductor index dropping about 6% to 7%. Drivers included a seventh straight S&P 500 decline, a faded Anthropic IPO bounce and new US chip export rules affecting TSMC and Samsung shipments to China. The shares trade well below their 50-day average near USD 60, and the 52-week range runs from USD 8.44 to USD 143.16. Indium phosphide is a compound semiconductor material used in lasers and photodetectors that carry data in optical links, and AI data centers need many of them. Demand growth has outpaced supply, which is why customers such as Lumentum have made prepayments to secure wafers.

Record Results and China Exposure

Third quarter revenue reached a record USD 73.4 million, up 162% from a year earlier, with an indium phosphide backlog above USD 500 million and a USD 43.5 million prepayment from Lumentum. The company plans to double indium phosphide capacity again in 2027. AXT is especially exposed to China because its wafers are made there, and export-permit risk persists. B. Riley is Neutral with a USD 43 target after a cut. The market Capitalization is about USD 1.99 billion and the trailing price to Earnings ratio is 66.99. A prepayment is cash paid in advance for future deliveries, so it signals commitment from the customer and helps the supplier fund capacity. Plans to double capacity again in 2027 depend on permits and equipment, and China-based Manufacturing means export licenses can delay shipments.

Risks: Stretched Valuation and Permits

The bearish view is that valuation is stretched at roughly 27 times sales, so the market already discounts a long runway of exceptional growth, and any stumble could compress the multiple sharply. Argus holds a Hold rating with low management and safety subratings. The bullish view is that the shares trade at a discount to a critical photonics supplier's prospects and that a Buy rating with a USD 57 target implies about 50% upside. Durability of margins, backlog conversion and China export permits are the key questions, along with Tongmei exposure. A fall of 13% can extend or reverse. The shares have fallen far below the 52-week high of USD 143.16, so the stock has given back most of its gains in a short time. At 27 times sales, the valuation leaves little room for any delay, which explains why sector sell-offs hit the stock hard. A broad optical sell-off can quickly reverse if sentiment recovers, but export rules can also change quickly, so investors treat the China exposure as a key swing factor.

Where Things Stand

AXT (NASDAQ:AXTI) fell because an AI and optical chip rout hit a China-exposed supplier, despite record revenue of USD 73.4 million and a backlog above USD 500 million. Capacity doubling and a Lumentum prepayment support the case. Against that, valuation is stretched, China export permits are uncertain and targets were cut. Permits and backlog conversion will decide the next move. A drop of this size shows how crowded the optical trade had become.